Daily Archives

October 3, 2013

Fenway is now enrolling participants in a phase II microbicde trial.

Fenway One of 8 Sites Worldwide Enrolling Participants in First-Ever Phase II Microbicide Trial

By | HIV/AIDS, The Fenway Institute | No Comments
Taking an important step toward the development of a product to prevent HIV infections associated with unprotected anal sex, researchers on October 2 announced the launch of a global Phase II clinical trial of a potential rectal microbicide. The trial, led by the U.S. National Institutes of Health (NIH)-funded Microbicide Trials Network (MTN), is testing the rectal use of a reduced glycerin gel formulation of the antiretroviral drug tenofovir. The Fenway Institute is one of 8 study sites worldwide that will be enrolling study participants. Known as MTN-017, the Phase II study will enroll 186 HIV-negative men who have sex 
Read More